![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Pharmaceutical Solutions Fzco Dubai Ae, based in U.A.E, is a pharmaceutical company.
One of their significant offerings is Aripiprazole, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2015-191 - Rev 00
This Chemical Type CEP, issued on April 19, 2017, remains in force until July 27, 2021, ensuring its reliability within the pharmaceutical industry.
Substance Number 2617 associated with this CEP further emphasizes